Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06487585
PHASE4

ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

Sponsor: University of Maryland St. Joseph Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.

Official title: Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-05-06

Completion Date

2026-02

Last Updated

2025-12-22

Healthy Volunteers

Yes

Interventions

DRUG

Angiotensin II

Angiotensin II: Starting dose of 2.5 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.

Locations (1)

University of Maryland St. Joseph Medical Center

Towson, Maryland, United States